Article
Upstream Bio Releases Topline Data From Phase 2 VALIANT Trial Of Verekitug For Severe Asthma, Meeting The Primary Endpoint Of Annualized Asthma Exacerbation Rate
- Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing.
- Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens.
- Verekitug was generally well tolerated, with a safety profile consistent with prior studies.
- Over 90% of eligible patients have rolled over to the Phase 2 VALOUR long-term extension study.
- Upstream Bio to advance verekitug into Phase 3 trials in severe asthma and CRSwNP following planned regulatory interactions
Comments
- No comments yet. Be the first to comment!